Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report ...

Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...

While data on functional endpoints are still to come, Avidity Biosciences Inc. executives said the firm is moving ahead with ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company with a market capitalization of $3.74 billion, has announced positive topline data from its Phase 1/2 EXPLORE44 trial ...

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones ...